Karyn S. Eilber

3 weeks ago | urologytimes.com | Karyn S. Eilber |Benjamin P. Saylor

The recent release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction]/[American Urogynecologic Society] Guideline” has been met with praise by health care professionals. Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for genitourinary syndrome of menopause (GSM).

1 month ago | urologytimes.com | Karyn S. Eilber |Benjamin P. Saylor

One of many notable highlights from the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada was the release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction]/[American Urogynecologic Society] Guideline.” In an interview with Urology Times®, described the significance of the new document.

1 month ago | urologytimes.com | Karyn S. Eilber |Benjamin P. Saylor

The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations, including a thorough discussion of the treatment with patients. “Most people are not aware that Botox [for OAB exists], and most people are not aware that there is also neuromodulation, so I think it's very important to bring those up, just to put them in their awareness, so they can do their own research, even after the visit is complete,” said Karyn S.

1 month ago | urologytimes.com | Karyn S. Eilber |Benjamin P. Saylor

The landscape of treatment for overactive bladder (OAB) encompasses several lines of therapeutic options, one of which is onbotulinumtoxinA (onabotA, Botox). In a recent interview with Urology Times®, Karyn S. Eilber, MD, explained the importance of confirming the diagnosis of OAB before outlining treatment options. “Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan.